CNS Pharmaceuticals

CNSPNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$7.627 M

$5.22 +2.13%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

-$16.0K

Loss-making

Shares outstanding

1,461,449

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#445LongeveronLGVN$7.81M
#446Traws PharmaTRAW$7.68M
#447CNS PharmaceuticalsCNSP$7.63M
#448InMed PharmaceuticalsINM$7.58M
#449Acurx PharmaceuticalsACXP$7.39M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of CNS Pharmaceuticals, worth $10.0K. Grants and option exercises are excluded.

Michal Fisher$10.0K
2,000 shares at $5.00 on 18 May 2026 · filed 18 Aug 2026

What if CNS Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.3T

$20,715,094

Per share 3,969,473× higher

Bitcoin $1.72T

$1,176,780

Per share 225,497× higher

Nvidia $5.48T

$3,749,606

Per share 718,508× higher

Or at a round number

$10.0M $20.0M $50.0M $100.0M

Where these numbers come from

Share counts and financials for CNS Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.